- Home
- ENTA
as 03-28-2025 4:00pm EST
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 154.0M | IPO Year: | 2013 |
| Target Price: | $17.25 | AVG Volume (30 days): | 234.3K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.71 - $17.80 | Next Earning Date: | 05-05-2025 |
| Revenue: | $66,590,999 | Revenue Growth: | -9.55% |
| Revenue Growth (this year): | -5.31% | Revenue Growth (next year): | -12.23% |
Stock Insider Trading Activity of Enanta Pharmaceuticals Inc. (ENTA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Luly Jay R. | ENTA | President and CEO | Feb 12 '25 | Buy | $5.69 | 45,000 | $256,050.00 | 846,638 |
Latest Enanta Pharmaceuticals Inc. News
ENTA Breaking Stock News: Dive into ENTA Ticker-Specific Updates for Smart Investing
Business Wire
12 days ago
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Business Wire
17 days ago
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium
Simply Wall St.
a month ago
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns
Simply Wall St.
a month ago
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock
Zacks
a month ago
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 02/13/2025
Zacks
2 months ago
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Associated Press Finance
2 months ago
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot
Compare ENTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ENTA Enanta Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.